Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Nutritional deterioration in
cancer: the role of disease and diet. Clin Oncol (R Coll Radiol) 2003; 15: 443-50.
2.
Arends J, Bodoky G, Bozzetti F et al. ESPEN Guidelines on Enteral Nutrition: Nonsurgical oncology. Clin Nutr 2006; 25: 245-59.
3.
Mazaki T, Ishii Y, Murai I. Immunoenhancing enteral and parenteral nutrition for
gastrointestinal surgery: a multiple-treatments meta-analysis. Ann Surg 2015; 261:
662-9.
4.
Klek S, Szybinski P, Szczepanek K. Perioperative immunonutrition in surgical
cancer patients: a summary of a decade of research. World J Surg 2014; 38: 803-12.
5.
Caro MMM, Laviano A, Pichard C. Nutritional intervention and quality of life in
adult oncology patients. Clinical Nutrition 2007; 26: 289-301.
6.
Bozzetti F, Zupec-Kania B. Toward a cancer-specific diet. Clinical Nutrition 2016;
35: 1188-95.
7.
Wallengren O, Bosaeus I, Lundholm K. Dietary energy density, inflammation and
energy balance in palliative care cancer patients. Clin Nutr 2013; 32: 88-92.
8.
Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg Effect: The
Metabolic Requirements of Cell Proliferation. Science 2009; 324: 1029-33.
9.
Turati F, Galeone C, Augustin LSA, La Vecchia C. Glycemic Index, Glycemic Load
and Cancer Risk: An Updated Meta-Analysis. Nutrients 2019; 11.
10.
Korber J, Pricelius S, Heidrich M, Muller MJ. Increased lipid utilization in weight
losing and weight stable cancer patients with normal body weight. Eur J Clin Nutr
1999; 53: 740-5.
11.
Arends J, Bachmann P, Baracos V et al. ESPEN guidelines on nutrition in cancer
patients. Clin Nutr 2017; 36: 11-48.
12.
Soldati L, Di Renzo L, Jirillo E et al. The influence of diet on anti-cancer immune
responsiveness. J Transl Med 2018; 16: 75.
13.
Golzar FAK, Fathi R, Mahjoub S. High-fat diet leads to adiposity and adipose tissue
inflammation: the effect of whey protein supplementation and aerobic exercise
training. Appl Physiol Nutr Metab 2019; 44: 255-62.
14.
Cho HJ, Kwon GT, Park H et al. A High-Fat Diet Containing Lard Accelerates
Prostate Cancer Progression and Reduces Survival Rate in Mice: Possible
Contribution of Adipose Tissue-Derived Cytokines. Nutrients 2015; 7: 2539-61.
15.
Tang FY, Pai MH, Chiang EP. Consumption of high-fat diet induces tumor
progression and epithelial-mesenchymal transition of colorectal cancer in a mouse
- 104 -
xenograft model. J Nutr Biochem 2012; 23: 1302-13.
16.
Philip B, Roland CL, Daniluk J et al. A high-fat diet activates oncogenic Kras and
COX2 to induce development of pancreatic ductal adenocarcinoma in mice.
Gastroenterology 2013; 145: 1449-58.
17.
Park H, Kim M, Kwon GT et al. A high-fat diet increases angiogenesis, solid tumor
growth, and lung metastasis of CT26 colon cancer cells in obesity-resistant BALB/c
mice. Mol Carcinog 2012; 51: 869-80.
18.
Kimura Y, Sumiyoshi M. High-fat, high-sucrose, and high-cholesterol diets
accelerate tumor growth and metastasis in tumor-bearing mice. Nutr Cancer 2007;
59: 207-16.
19.
Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in
cancer cells. Oncogenesis 2016; 5: e189.
20.
Teng KT, Chang CY, Chang LF, Nesaretnam K. Modulation of obesity-induced
inflammation by dietary fats: mechanisms and clinical evidence. Nutr J 2014; 13:
12.
21.
Tang F-Y, Pai M-H, Chiang E-PI. Consumption of high-fat diet induces tumor
progression and epithelial-mesenchymal transition of colorectal cancer in a mouse
xenograft model. Journal of Nutritional Biochemistry 2012; 23: 1302-13.
22.
Kim EJ, Choi MR, Park H et al. Dietary fat increases solid tumor growth and
metastasis of 4T1 murine mammary carcinoma cells and mortality in obesityresistant BALB/c mice. Breast Cancer Res 2011; 13: R78.
23.
Mavropoulos JC, Buschemeyer WC, 3rd, Tewari AK et al. The effects of varying
dietary carbohydrate and fat content on survival in a murine LNCaP prostate
cancer xenograft model. Cancer Prev Res (Phila) 2009; 2: 557-65.
24.
Kim WG, Park JW, Willingham MC, Cheng SY. Diet-induced obesity increases
tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.
Endocrinology 2013; 154: 2936-47.
25.
Bahr I, Goritz V, Doberstein H et al. Diet-Induced Obesity Is Associated with an
Impaired NK Cell Function and an Increased Colon Cancer Incidence. J Nutr
Metab 2017: 1-14.
26.
White PB ZK, Swartz-Basile DA, Wang SS, Lillemoe KD, Pitt HA, Zyromski NJ.
Obesity, but not high-fat diet, promotes murine pancreatic cancer growth. J
Gastrointest Surg 2012; 16: 1680-5.
27.
Parisi L, Gini E, Baci D et al. Macrophage Polarization in Chronic Inflammatory
Diseases: Killers or Builders? J Immunol Res 2018; 2018: 8917804.
28.
Shrihari TG. Dual role of inflammatory mediators in cancer. Ecancermedicalscience
- 105 -
2017; 11: 721.
29.
Vykhovanets EV, Shankar E, Vykhovanets OV et al. High-fat diet increases NFkappaB signaling in the prostate of reporter mice. Prostate 2011; 71: 147-56.
30.
Rogero MM, Calder PC. Obesity, Inflammation, Toll-Like Receptor 4 and Fatty
Acids. Nutrients 2018; 10.
31.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose Expression of TumorNecrosis-Factor-Alpha - Direct Role in Obesity-Linked Insulin Resistance. Science
1993; 259: 87-91.
32.
McClellan JL, Davis JM, Steiner JL et al. Linking tumor-associated macrophages,
inflammation, and intestinal tumorigenesis: role of MCP-1. Am J Physiol
Gastrointest Liver Physiol 2012; 303: G1087-95.
33.
Fujimoto H, Sangai T, Ishii G et al. Stromal MCP-1 in mammary tumors induces
tumor-associated macrophage infiltration and contributes to tumor progression.
International Journal of Cancer 2009; 125: 1276-84.
34.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading
role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
35.
Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix
metalloproteinase-9 requires endogenous TNF-alpha. European Journal of
Immunology 2002; 32: 404-12.
36.
Ajuwon KM, Spurlock ME. Palmitate activates the NF-kappaB transcription factor
and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr 2005; 135:
1841-6.
37.
Shevchenko I, Karakhanova S, Soltek S et al. Low-dose gemcitabine depletes
regulatory T cells and improves survival in the orthotopic Panc02 model of
pancreatic cancer. Int J Cancer 2013; 133: 98-107.
38.
Alwarawrah Y, Kiernan K, MacIver NJ. Changes in Nutritional Status Impact
Immune Cell Metabolism and Function. Front Immunol 2018; 9: 1055.
39.
Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat
Immunol 2017; 18: 843-50.
40.
Street SEA, Cretney E, Smyth MJ. Perforin and interferon-gamma activities
independently control tumor initiation, growth, and metastasis. Blood 2001; 97:
192-7.
41.
Meza-Perez S, Randall TD. Immunological Functions of the Omentum. Trends
Immunol 2017; 38: 526-36.
42.
Higashijima J, Shimada M, Chikakiyo M et al. Effect of splenectomy on antitumor
immune system in mice. Anticancer Res 2009; 29: 385-93.
- 106 -
43.
Hotta Y, Kasuya H, Bustos I et al. Curative effect of HF10 on liver and peritoneal
metastasis mediated by host antitumor immunity. Oncolytic Virother 2017; 6: 31-8.
44.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune
tolerance. Cell 2008; 133: 775-87.
45.
Deng G. Tumor-infiltrating regulatory T cells: origins and features. Am J Clin Exp
Immunol 2018; 7: 81-7.
46.
Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor
immunity. Cancer Immunol Res 2014; 2: 194-9.
47.
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas.
Journal of Clinical Investigation 2012; 122: 787-95.
48.
Namgaladze D, Brune B. Macrophage fatty acid oxidation and its roles in
macrophage polarization and fatty acid-induced inflammation. Biochim Biophys
Acta 2016; 1861: 1796-807.
49.
Batista-Gonzalez A, Vidal R, Criollo A, Carreno LJ. New Insights on the Role of
Lipid Metabolism in the Metabolic Reprogramming of Macrophages. Front Immunol
2019; 10: 2993.
50.
Michalek RD, Gerriets VA, Jacobs SR et al. Cutting edge: distinct glycolytic and
lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T
cell subsets. J Immunol 2011; 186: 3299-303.
51.
Pacella I, Piconese S. Immunometabolic Checkpoints of Treg Dynamics: Adaptation
to Microenvironmental Opportunities and Challenges. Front Immunol 2019; 10:
1889.
52.
Khodadadi S, Sobhani N, Mirshekar S et al. Tumor Cells Growth and Survival Time
with the Ketogenic Diet in Animal Models: A Systematic Review. Int J Prev Med
2017; 8: 35.
53.
Freitas RDS, Campos MM. Protective Effects of Omega-3 Fatty Acids in CancerRelated Complications. Nutrients 2019; 11.
54.
Andrejeva G, Rathmell JC. Similarities and Distinctions of Cancer and Immune
Metabolism in Inflammation and Tumors. Cell Metabolism 2017; 26: 49-70.
55.
Mavropoulos JC, Buschemeyer WC, Tewari AK et al. The Effects of Varying Dietary
Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer
Xenograft Model. Cancer Prev Res 2009; 2: 557-65.
56.
D'Eliseo D, Velotti F. Omega-3 Fatty Acids and Cancer Cell Cytotoxicity:
Implications for Multi-Targeted Cancer Therapy. J Clin Med 2016; 5.
57.
Apte SA, Cavazos DA, Whelan KA, Degraffenried LA. A Low Dietary Ratio of
Omega-6 to Omega-3 Fatty Acids May Delay Progression of Prostate Cancer.
- 107 -
Nutrition and Cancer-an International Journal 2013; 65: 556-62.
58.
Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty
acids. Biomedicine & Pharmacotherapy 2002; 56: 365-79.
59.
Zhu L, Zhao Q, Yang T et al. Cellular metabolism and macrophage functional
polarization. Int Rev Immunol 2015; 34: 82-100.
60.
Varshney P, Yadav V, Saini N. Lipid rafts in immune signalling: current progress
and future perspective. Immunology 2016; 149: 13-24.
61.
Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins
Leukot Essent Fatty Acids 2018; 132: 41-8.
62.
D'Eliseo D, Velotti F. Omega-3 Fatty Acids and Cancer Cell Cytotoxicity:
Implications for Multi-Targeted Cancer Therapy. Journal of Clinical Medicine 2016;
5.
63.
Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front
Oncol 2014; 4: 64.
64.
Loi S, Dushyanthen S, Beavis PA et al. RAS/MAPK Activation Is Associated with
Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer:
Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint
Inhibitors. Clinical Cancer Research 2016; 22: 1499-509.
65.
Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012;
188: 21-8.
66.
Hughes-Fulford M, Tjandrawinata RR, Li CF, Sayyah S. Arachidonic acid, an
omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma
cells. Carcinogenesis 2005; 26: 1520-6.
67.
Mizuno R, Kawada K, Sakai Y. Prostaglandin E2/EP Signaling in the Tumor
Microenvironment of Colorectal Cancer. Int J Mol Sci 2019; 20.
68.
Seki S, Nakashima H, Nakashima M, Kinoshita M. Antitumor Immunity Produced
by the Liver Kupffer Cells, NK Cells, NKT Cells, and CD8(+) CD122(+) T Cells. Clin
Dev Immunol 2011.
69.
Wang J, Zhang L, Kang D et al. Activation of PGE2/EP2 and PGE2/EP4 signaling
pathways positively regulate the level of PD-1 in infiltrating CD8(+) T cells in
patients with lung cancer. Oncol Lett 2018; 15: 552-8.
70.
Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of
anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
71.
Matson V, Fessler J, Bao R et al. The commensal microbiome is associated with
anti-PD-1 efficacy in metastatic melanoma patients. Science 2018; 359: 104-+.
72.
Kumar R, Yu F, Zhen YH et al. PD-1 blockade restores impaired function of ex vivo
- 108 -
expanded CD8(+) T cells and enhances apoptosis in mismatch repair deficient
EpCAM(+)PD-L1(+) cancer cells. Onco Targets Ther 2017; 10: 3453-65.
73.
Lamberti MJ, Pansa MF, Vera RE et al. Transcriptional activation of HIF-1 by a
ROS-ERK axis underlies the resistance to photodynamic therapy. PLoS One 2017;
12: e0177801.
74.
D'Ignazio L, Batie M, Rocha S. Hypoxia and Inflammation in Cancer, Focus on HIF
and NF-kappaB. Biomedicines 2017; 5.
75.
D'Ignazio L, Bandarra D, Rocha S. NF-kappaB and HIF crosstalk in immune
responses. FEBS J 2016; 283: 413-24.
76.
Salaroglio IC, Mungo E, Gazzano E et al. ERK is a Pivotal Player of ChemoImmune-Resistance in Cancer. Int J Mol Sci 2019; 20.
77.
Liu Q, Song J, Pan Y et al. Wnt5a/CaMKII/ERK/CCL2 axis is required for tumorassociated macrophages to promote colorectal cancer progression. Int J Biol Sci
2020; 16: 1023-34.
78.
Serini S, Calviello G. Modulation of Ras/ERK and Phosphoinositide Signaling by
Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role
in Combination with Targeted Drugs. Nutrients 2017; 9.
79.
Chen B, Liu J, Ho TT et al. ERK-mediated NF-kappaB activation through ASIC1 in
response to acidosis. Oncogenesis 2016; 5: e279.
80.
Parida S, Siddharth S, Sharma D. Adiponectin, Obesity, and Cancer: Clash of the
Bigwigs in Health and Disease. Int J Mol Sci 2019; 20.
81.
Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review.
Br J Cancer 2006; 94: 1221-5.
82.
Izadi V, Farabad E, Azadbakht L. Serum adiponectin level and different kinds of
cancer: a review of recent evidence. ISRN Oncol 2012; 2012: 982769.
83.
Kato M, Watabe K, Tsujii M et al. Adiponectin inhibits murine pancreatic cancer
growth. Dig Dis Sci 2014; 59: 1192-6.
84.
Neschen S, Morino K, Rossbacher JC et al. Fish oil regulates adiponectin secretion
by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in
mice. Diabetes 2006; 55: 924-8.
85.
Gray B, Steyn F, Davies PS, Vitetta L. Omega-3 fatty acids: a review of the effects
on adiponectin and leptin and potential implications for obesity management. Eur J
Clin Nutr 2013; 67: 1234-42.
86.
Weber DD, Aminzadeh-Gohari S, Tulipan J et al. Ketogenic diet in the treatment of
cancer - Where do we stand? Mol Metab 2020; 33: 102-21.
87.
Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric
- 109 -
oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One
2013; 8: e65522.
88.
Newman JC, Covarrubias AJ, Zhao M et al. Ketogenic Diet Reduces Midlife
Mortality and Improves Memory in Aging Mice. Cell Metab 2017; 26: 547-57 e8.
89.
Sremanakova J, Sowerbutts AM, Burden S. A systematic review of the use of
ketogenic diets in adult patients with cancer. J Hum Nutr Diet 2018; 31: 793-802.
90.
Hagihara K, Kajimoto K, Osaga S et al. Promising Effect of a New Ketogenic Diet
Regimen in Patients with Advanced Cancer. Nutrients 2020; 12.
91.
Radzikowska U, Rinaldi AO, Celebi Sozener Z et al. The Influence of Dietary Fatty
Acids on Immune Responses. Nutrients 2019; 11.
- 110 -
...
論文の公開元へ
